Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Abeona Therapeutics Inc. (ABEO)

0.1916   -0.016 (-7.88%) 07-02 19:34
Open: 0.2018 Pre. Close: 0.208
High: 0.205 Low: 0.188
Volume: 2,740,106 Market Cap: 28(M)
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.21 - 0.21 0.21 - 0.21
Low: 0.19 - 0.19 0.19 - 0.19
Close: 0.21 - 0.21 0.21 - 0.21

Technical analysis

as of: 2022-07-01 4:19:46 PM
Overall:       
Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 0.24     One year: 0.29
Support: Support1: 0.17    Support2: 0.15
Resistance: Resistance1: 0.21    Resistance2: 0.24
Pivot: 0.17
Moving Average: MA(5): 0.19     MA(20): 0.17
MA(100): 0.22     MA(250): 0.6
MACD: MACD(12,26): 0     Signal(9): 0
Stochastic oscillator: %K(14,3): 78.9     %D(3): 75.5
RSI: RSI(14): 56.4
52-week: High: 1.53  Low: 0.12
Average Vol(K): 3-Month: 1,748 (K)  10-Days: 2,174 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ ABEO ] has closed below upper band by 24.1%. Bollinger Bands are 10.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Fri, 01 Jul 2022
Dashboard Camera Market Statistics: 2020 & Beyond by Aiptek Inc., Abeo Company Co. Ltd, Qrontech Co. Ltd, Dod Tec, Bulls-I Vehicle Drive Recorders, Delphi Automotive Systems Pvt Ltd – Indian Defence News - Indian Defence News

Thu, 30 Jun 2022
StockNews.com Initiates Coverage on Abeona Therapeutics (NASDAQ:ABEO) - Defense World

Tue, 28 Jun 2022
Car DVR Market Competition Outlook & Key Statistics by ABEO Technology, Amcrest Technologies, CNSLink, DOD Tec, Garmin, Honeywell, and more – Indian Defence News - Indian Defence News

Mon, 27 Jun 2022
US Anesthesiology Service Market Size, Scope and Forecast | Abeo, AnesthesiaBillingBridge, Blackstone (TeamHealth), Freelance Anesthesia, KKR & Co. Inc. (Envision Healthcare Corporation), Mednax, National Anesthesia Services, PhyMed Healthcar - Designer Women

Mon, 27 Jun 2022
Critical Analysis: Abeona Therapeutics (NASDAQ:ABEO) & Palatin Technologies (NYSE:PTN) - Defense World

Thu, 23 Jun 2022
ABEO Held For 'Misbehaving' With Girl Student In Kendrapara's Rajnagar - Pragativadi

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 147 (M)
% Held by Insiders 1.2402e+008 (%)
% Held by Institutions 10.3 (%)
Shares Short 4,660 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -5.395e+007
EPS Est Next Qtl -0.19
EPS Est This Year -0.7
EPS Est Next Year -0.77
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -1
Return on Assets (ttm) 709.3
Return on Equity (ttm) -36.4
Qtrly Rev. Growth 3.35e+006
Gross Profit (p.s.) 0
Sales Per Share -95.72
EBITDA (p.s.) -200671
Qtrly Earnings Growth -0.9
Operating Cash Flow 0 (M)
Levered Free Cash Flow -66 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.01
Price to Cash Flow 1.35

Stock Dividends

Dividend 0
Forward Dividend 4.4e+006
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.